EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping

Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten Weber, Miguel Martin, Frederik Marmé, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Sabine Seiler, Harry D Bear, Agnieszka K Witkiewicz und 28 weitere

Cancer Cell · 2025-02 · 43 (2) · 232-247.e4

DOI: 10.1016/j.ccell.2025.01.002 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Cell, 2025-02. Verfasst von Carsten Denkert und 39 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany. Electronic address: carsten.denkert@uni-marbur…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, German Cancer Aid, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBreast NeoplasmsFemaleHumansMiddle AgedGenetic HeterogeneityNeoadjuvant TherapyPrognosisErb-b2 Receptor Tyrosine KinasesTranscriptome

Stichwörter der Autor:innen

breast cancermolecular profilingneoadjuvant therapytherapy-induced heterogeneity

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany. Electronic address: carsten.denkert@uni-marburg.de.
  • German Breast Group, Neu-Isenburg, Germany.
  • Department of Gynecology and Obstetrics, Goethe-University, Frankfurt, Germany.
  • Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; Spanish Breast Cancer Group, GEICAM, Madrid, Spain.
  • Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany.
  • Helios Kliniken Berlin-Buch, Berlin, Germany; AGO-B Study Group, Erlangen, Germany.

Förderung

  • Pfizer
  • German Cancer Aid
  • Bundesministerium für Bildung und Forschung
  • Bundesministerium für Forschung und Technologie

Zitieren

APA

Denkert, C., Rachakonda, S., Karn, T., Weber, K., Martin, M., Marmé, F., Untch, M., Bonnefoi, H., Kim, S. B., Seiler, S., Bear, H. D., Witkiewicz, A. K., Im, S. A., DeMichele, A., Pehl, A., Van't Veer, L., McCarthy, N., Stiewe, T., Jank, P., …, & Loibl, S. (2025). Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping. Cancer Cell, 43(2), 232-247.e4. https://doi.org/10.1016/j.ccell.2025.01.002

Vancouver

Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping. Cancer Cell. 2025;43(2):232-247.e4. doi:10.1016/j.ccell.2025.01.002

BibTeX
@article{Denkert2025,
  author = {Denkert, Carsten and Rachakonda, Sivaramakrishna and Karn, Thomas and Weber, Karsten and Martin, Miguel and Marmé, Frederik and Untch, Michael and Bonnefoi, Hervé and Kim, Sung-Bae and Seiler, Sabine and Bear, Harry D and Witkiewicz, Agnieszka K and Im, Seock-Ah and DeMichele, Angela and Pehl, Anika and Van't Veer, Laura and McCarthy, Nicole and Stiewe, Thorsten and Jank, Paul and Gelmon, Karen A and García-Sáenz, José A and Westhoff, Christina C and Kelly, Catherine M and Reimer, Toralf and Felder, Bärbel and Olivé, Mireia Melé and Knudsen, Erik S and Turner, Nicholas and Rojo, Federico and Schmitt, Wolfgang D and Fasching, Peter A and Teply-Szymanski, Julia and Zhang, Zhe and Toi, Masakazu and Rugo, Hope S and Gnant, Michael and Makris, Andreas and Holtschmidt, Johannes and Nekljudova, Valentina and Loibl, Sibylle},
  title = {Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {232--247.e4},
  doi = {10.1016/j.ccell.2025.01.002}
}
Kostenlos starten →